Olatec Therapeutics to Conduct a Phase 2 Clinical Trial in Patients with Early Parkinson s Disease with its NLRP3 Inhibitor, Dapansutrile streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Olatec Therapeutics, Inc. (Olatec), a leader in the developing class of selective NLRP3 inhibitors, today announced that Cure Parkinson's granted an award to initiate a Phase 2 clinical trial investigating the potential of oral dapansutrile to slow.
Seeks dismissal of all claims related to ‘793 patent based on prior findings of invalidity which have been affirmed by the Federal CircuitRequests declaration that ‘327 patent is not infringed, is.